How could the STAMPEDE trial shape prostate cancer care?

In this video interview, filmed at the ESMO 2022 Congress (9–13 September, Paris, France), we speak with Marc Stapley – CEO of Veracyte (CA, USA) and Elai Davicioni Ph.D. – Urology Medical Director of Veracyte about exciting developments in genomic tests. We also explore the STAMPEDE trial, which aims to provide evidence as to what is the best way of treating men with newly diagnosed advanced prostate cancer.

The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Oncology Central or Future Science Group.

Video edit by James Harvie (Future Science Group, London, UK)